Abbott to Collaborate with Janssen Pharma, Pharmacyclics to Develop Companion Test for Investigational Leukemia Therapy

Abbott (NYSE: ABT ) announced today that it will collaborate with Janssen Biotech, Inc. and Pharmacyclics, Inc. (NASDAQ: PCYC ) to explore the benefits of Abbott's proprietary FISH (fluorescence in situ hybridization) technology for use in developing a molecular companion diagnostic test to identify patients with a genetic subtype of chronic lymphocytic leukemia